Scarica l'app Stockscreener
19.54
1.19%
0.23
Dopo l'orario di chiusura:
19.56
0.02
+0.10%
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Nuvectis Pharma Inc (NVCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NVCT|Nuvectis Pharma Inc|Price:19.530|Chg%:+0.220 - TradingKey
NVCT|Nuvectis Pharma Inc|Price:19.310|Chg%:-0.840 - TradingKey
Nuvectis Pharma Inc (NVCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nuvectis Pharma Inc (NVCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nuvectis Pharma Inc (NVCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvectis Pharma Inc (NVCT) Cash Flow - TradingKey
TradingKey - TradingKey
Maxim Group Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $39 - Moomoo
China approves Nuvectis’ ciprocopan for blood disorder PNH - Investing.com UK
Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39 - TipRanks
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor - TipRanks
Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor - Benzinga
Correction: Nuvectis Announces Marketing Approval of Ciprocopan in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors - Investing News Network
Nuvectis Pharma Announces First Global Approval of Once-Daily Oral Complement Factor B Inhibitor Ciprocopan in China for PNH - Quiver Quantitative
Ciprocopan Is World's First Approved Once-Daily Oral Factor B Inhibitor - Stock Titan
China approves ciprocopan, first oral once-dail... - Pluang
China approves Nuvectis’ ciprocopan for blood disorder PNH By Investing.com - Investing.com Australia
Nuvectis Pharma receives China approval for Ciprocopan to treat PNH in patients not given complement inhibitors - Traders Union
Nuvectis Drug Reached 12 g/dL in 59.5% of PNH Patients - Stock Titan
Nuvectis' NXP100 Just Achieved The First Marketing Approval Ever For A Once-Daily Oral Factor B Inhibitor - Menafn
NVCT Q1 2026 Earnings: EPS Beat Estimates as Company Advances PipelineEarnings Yield Analysis - dars.gov.et
Nuvectis Pharma Prices $100 Million Public Offering to Advance Pipeline - citybuzz -
Nuvectis Pharma Targets a $9.8 Billion Oral PNH Market With Late-Stage NXP100 - t.co
Wall Street analysts see a 61.46% upside in Nuvectis Pharma (NVCT): Can the stock really move this high? - MSN
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data - Cantech Letter
Nuvectis Pharma expands into rare diseases with... - Pluang
Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data - FinanzNachrichten.de
How (NVCT) Movements Inform Risk Allocation Models - Stock Traders Daily
Catalyst watch: SpaceX initiations, Sun Valley Conference, PepsiCo earnings - MSN
NVCT Stock Price, Quote & Chart - ChartMill
Nuvectis Pharma’s NXP900 Combo Trial Adds Fresh Momentum to NVCT in EGFR Lung Cancer - TipRanks
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush - TipRanks
Nuvectis Pharma Inc (NVCT) News, Articles, Events & Latest Updates - Stocktwits
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? - Yahoo Finance
Roth MKM Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Nuvectis Pharma Price Target Raised to $33.00/Share From $20.00 by Roth Capital - Moomoo
Roth Capital raises Nuvectis target to $33 - scanx.trade
Roth MKM Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $33 - Moomoo
An Insider Of Nuvectis Pharma Picks Up 1.5% More Stock - 富途牛牛
Trading Systems Reacting to (NVCT) Volatility - Stock Traders Daily
What makes Nuvectis Pharma, Inc. (NVCT) a strong momentum stock: Buy now? - MSN
Nuvectis Pharma announces public share offering to support drug programs - MSN
Nuvectis Pharma Announces Major Public Equity Offering - The Globe and Mail
Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvect - GuruFocus
Nuvectis Pharma CEO Ron Bentsur buys $250,000 in company stock By Investing.com - Investing.com Nigeria
Nuvectis Pharma CEO Ron Bentsur buys $250,000 in company stock - Investing.com
[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity - Stock Titan
Form 4 Nuvectis Pharma Inc For: 1 July By Investing.com - Investing.com India
Nuvectis Pharma 10% owner Mosseri buys $916k in shares - Investing.com UK
Nuvectis Pharma 10% owner Mosseri buys $916k in shares By Investing.com - Investing.com Australia
Nuvectis Pharma Insider Bought Shares Worth $916,000, According to a Recent SEC Filing - Moomoo
Nuvectis Pharma (NVCT) CEO Ron Bentsur buys $250,000 in shares - Stock Titan
Nuvectis: 'Hold' On NXP800 Removal And Newly Licensed Candidates (NASDAQ:NVCT) - Seeking Alpha
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Nuvectis Raises $100M for Oncology Pivot - AllSci
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):